Table 4 Multivariate Cox regression model showing risk factors associated with incident MDR-TB in the training and validation sets (N = 1836).

From: Nomogram for individualized prediction of incident multidrug-resistant tuberculosis after completing pulmonary tuberculosis treatment

Variables

Training set (n = 1719)*

Validation set (n = 117)*

No

HR (95% CI)

P value

No

HR (95% CI)

P value

Sociodemographic characteristics

Age < 60 years

1,108

1.25 (1.01–1.57)

0.049

69

1.37 (0.51–3.71)

0.531

Low-level FI

558

1.05 (0.56–1.99)

0.867

48

NA

NA

High-risk occupation

362

0.98 (0.78–1.22)

0.833

33

1.90 (0.78–4.65)

0.160

High school and below

1,270

1.22 (0.95–1.58)

0.125

87

NA

NA

Rural areas

554

1.13 (0.64–1.97)

0.256

36

NA

NA

A history of direct contact

225

2.71 (2.42–3.04)

< 0.001

26

2.34 (1.33–4.13)

0.003

Clinical characteristics

Passive MCF

418

2.38 (1.24–4.58)

0.009

35

1.28 (0.46–3.53)

0.639

HIV infection

56

2.36 (1.75–3.18)

< 0.001

9

1.32 (0.42–4.16)

0.640

CRT

308

1.36 (1.11–1.68)

0.004

43

1.83 (0.26–12.70)

0.540

Unsuccessful treatment

257

2.72 (2.20–3.37)

< 0.001

21

2.65 (1.06–6.62)

0.037

PTB treatment time (days)

1,719

NA

NA

117

1.03 (1.01–1.14)

0.016

TIOFMV (days)

1,586

1.00 (0.99–1.01)

0.368

108

NA

NA

FDC-2HRZE/4HR

91

0.90 (0.52–1.54)

0.692

6

NA

NA

2HRZES/6HRE

53

0.71 (0.47–1.06)

0.090

5

NA

NA

3HRZES/6HRE

43

2.18 (1.31–3.62)

0.003

14

0.71 (0.26–1.96)

0.510

Chest imaging

Excellent FCXE

220

0.71 (0.65–0.77)

< 0.001

22

NA

NA

DPC, months

706

1.18 (1.10–1.27)

< 0.001

38

1.51 (1.01–2.25)

0.046

DAF, months

1,692

1.21 (0.91–1.34)

0.253

109

NA

NA

Microbiological characteristics

FSC

1,350

1.00 (0.87–1.15)

0.978

94

0.71 (0.45–1.13)

0.148

DPSC, months

954

1.26 (1.10–1.44)

0.001

66

NA

NA

DNSC, months

396

0.90 (0.75–1.08)

0.997

28

0.95 (0.44–2.05)

0.896

  1. Data are shown as No., hazard ratio (95% CI), and P value.
  2. MDR-TB: multidrug-resistant tuberculosis; TB: tuberculosis; PTB: pulmonary tuberculosis; FI: family income; HIV: human immunodeficiency virus; HR: hazard ratio; MCF: mode of TB case finding; CRT: completing re-treated pulmonary TB treatment; TIOFMV: time from illness onset to the first medical visit; FDC: fixed-dose combination; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; S: streptomycin; CI: confidence interval; NA: not available; FCXE: frequencies of chest X-ray examination; DPC: duration of pulmonary cavities; DAF: duration of abnormal X-ray findings; FSC: frequencies of sputum culture; DPSC: duration of positive sputum culture; DNSC: duration of negative sputum culture.
  3. *Bold values are those that reach statistical significance (P < 0.05).